ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 97 filers reported holding ALBIREO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,734,516 | -27.2% | 265,364 | -34.8% | 0.10% | -35.1% |
| Q3 2022 | $7,876,000 | +67.9% | 406,833 | +72.3% | 0.15% | +64.4% |
| Q2 2022 | $4,690,000 | -20.9% | 236,147 | +18.9% | 0.09% | -10.0% |
| Q1 2022 | $5,926,000 | +82.3% | 198,651 | +42.4% | 0.10% | +92.3% |
| Q4 2021 | $3,250,000 | +828.6% | 139,551 | +1142.7% | 0.05% | +642.9% |
| Q3 2021 | $350,000 | -21.2% | 11,230 | -11.1% | 0.01% | -22.2% |
| Q2 2021 | $444,000 | -39.2% | 12,630 | -39.0% | 0.01% | -43.8% |
| Q1 2021 | $730,000 | -10.8% | 20,718 | -5.1% | 0.02% | -20.0% |
| Q4 2020 | $818,000 | +50.9% | 21,820 | +34.4% | 0.02% | +25.0% |
| Q3 2020 | $542,000 | +22.6% | 16,236 | -2.7% | 0.02% | +14.3% |
| Q2 2020 | $442,000 | +132.6% | 16,680 | +44.0% | 0.01% | +75.0% |
| Q1 2020 | $190,000 | -39.9% | 11,580 | -6.8% | 0.01% | -20.0% |
| Q4 2019 | $316,000 | – | 12,430 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |